Search

Displaying results 3011 - 3020 of 8974 in total
  1. Drug

    Norgestimate

    go.drugbank.com/drugs/DB00957
    ApprovedInvestigational

    [A191068] It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. … [A191068] It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat moderate acne vulgaris.

    Mixtures: TriNessa Lo, TriNessa LoCategories: Hormonal Contraceptives for Systemic Use
  2. Drug

    Sebetralstat

    go.drugbank.com/drugs/DB18305
    ApprovedInvestigational

    Sebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293]. … Food and Drug Administration approved sebetralstat on July 7, 2025, for treating acute HAE attacks in patients aged 12 years and older [L53533, L53538].

  3. Drug

    Metocurine iodide

    go.drugbank.com/drugs/DB00416
    ApprovedWithdrawn

    Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. … It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine

  4. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases. … [A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC.

  5. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … D2 receptors have been the most common target for antipsychotic agents used in the treatment of schizophrenia: the positive symptoms are thought to arise from overactivity in the mesolimbic dopaminergic

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Tesamorelin

    go.drugbank.com/drugs/DB08869
    ApprovedInvestigational

    Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection. … Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients

  7. Drug

    Cyproterone acetate

    go.drugbank.com/drugs/DB04839
    ApprovedInvestigational

    An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. … It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.

    Categories: Hormonal Contraceptives for Systemic Use, Contraceptive Agents, MaleSynonyms: Cyproterone 17-O-acetate
  8. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class. … It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    [A189063] Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. … The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.

  10. Drug

    Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15620
    ApprovedInvestigational

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

    Mixtures: Influvac Tetra, suspension for injection in pre-filled syringe, Vaxigrip Tetra, Suspension for Injection in Pre-filled Syringe